[1]张冰,徐俊,徐运,等.fMRI在阿尔茨海默病、额颞叶痴呆及路易体痴呆中的研究进展[J].国际放射医学核医学杂志,2010,34(5):303-307.[doi:10.3760/cma.j.issn.1673-4114.2010.05.015]
　ZHANG Bing,XU Jun,XU Yun,et al.The study of fMRI in Alzheimer’s disease, frontotemporal dementia and Lewy bodies dementia[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(5):303-307.[doi:10.3760/cma.j.issn.1673-4114.2010.05.015]
点击复制

fMRI在阿尔茨海默病、额颞叶痴呆及路易体痴呆中的研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
34
期数:
2010年第5期
页码:
303-307
栏目:
临床放射医学
出版日期:
1900-01-01

文章信息/Info

Title:
The study of fMRI in Alzheimer’s disease, frontotemporal dementia and Lewy bodies dementia
作者:
张冰1;  徐俊3;  徐运2;  朱斌1
1. 210008, 南京大学医学院附属鼓楼医院放射科;
2. 南京医科大学附属脑科医院神经内科;
3. 210008, 南京大学医学院附属鼓楼医院神经内科
Author(s):
ZHANG Bing1;  XU Jun3;  XU Yun2;  ZHU Bin1
Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanling 210008, China
关键词:
阿尔茨海默病; Lewy体病; 额颞叶痴呆; 磁共振成像
Keywords:
Alzheimer disease; Lewy body disease; Frontotemproal dementic; Magnetic resonance imaging
DOI:
10.3760/cma.j.issn.1673-4114.2010.05.015
摘要:
阿尔茨海默病(AD)、路易体痴呆(DLB)及额颞叶痴呆(FTD)是神经退变疾病导致痴呆的几种常见类型,但DLB及FTD常被误诊为AD。结构磁共振成像(sMRI)、弥散加权成像(DWI)及氢质子磁共振波谱分析可以为AD及相关疾病的诊断及鉴别诊断提供重要的支持证据。脑萎缩模式、表观弥散系数及各向异性分数分布模式、N-乙酰大冬氨酸和肌醇在颞叶、海马、顶叶及额叶的分布模式有助于鉴别AD、DLB及FTD,并与病理改变一致。
Abstract:
Alzheimer’s disease (AD), dementia with Lewy bodies(DLB) and frontotemporal dementia (FTD) are the main type of neurodegenerative diseases, but the FTD and DLB are always confused with AD.Structural MRI, diffusion-weighted imaging and proton magnetic resonance spectroscopy have the potential to support the diagnosis of AD and the relative disease. Brain atrophy pattern, apparent diffusion coefficient and fractional anisotropy pattern, the distribution mode of N-acetylaspartate and myo-inositol in temporal lobe,hippocampus, parietal lobe, frontal lobe could help to differentiate AD from FTD, DLB and those patterns are in accordance with the pathological changes.

参考文献/References:

[1] Davatzikos C, Resnick SM, Wu X, et al. Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRL Neuroimage, 2008, 41(4):1220-1227.
[2] Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol, 2010, 9(1):119-128.
[3] Dnbois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease:revising the NINCDS-ADRDA criteria. Lancet Neorol, 2007, 6(8):734-746.
[4] Krishnan S, Talley BD, Slavin MJ, et al. Current status of functional MR imaging, perfusion-weighted imaging, and diffusion-tensor imaging in Alzheimer’s disease diagnosis and research. Neuro-imaging Clin N Am, 2005, 15(4):853-868,xi.
[5] Jack CR Jr, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology, 2000, 55(4):484-489.
[6] Goldszal AF, Davatzikos C, Pham DL, et al. An image-processing system for qualitative and quantitative volumetric analysis of brain images. J Comput Assist Tomogr, 1998, 22(5):827-837.
[7] Fein G, Landman B, Tran H, et al. Statistical parametric mapping of brain morphology:sensitivity is dramatically increased by using brain-extracted images as inputs. Neuro-image, 2006, 30(4):1187-1195.
[8] Whitwell JL, Jack CR Jr. Neuroimaging in dementia. Neurol Clin, 2007, 25(3):843-857.
[9] Kantarci K, Petersen RC, Przybelski SA, et al. Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cere brovascular disease in mild cognitive impairment subtypes. Arch Neurol, 2008, 65(12):1621-1628.
[10] Whitwell JL, Przybelski SA, Weigand SD, et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer’s disease. Brain, 2007, 130(Pt7):1777-1786.
[11] Broe M, Hodges JR, Schofield E, et al. Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology, 2003, 60(6):1005-1011.
[12] Kitagaki H, Mori E, Yamaji S, et al. Frontotemporal dementia and Alzheimer disease:evaluation of cortical atrophy with automated hemispheric surface display generated with MR images. Radiology, 1998, 208(2):431-439.
[13] Laakso MP, Frisoni GB, Kononen M, et al. Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer’s disease:a morphometric MRI study. Biol Psychiatry, 2000, 47(12):1056-1063.
[14] No authors listed. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry, 1994, 57(4):416-418.
[15] Kenny ER, Burton E J, O’Brien JT. A volumetric magnetic resonance imaging study of entorhinal cortex volume in dementia with Lewy bodies. A comparison with Alzheimer’s disease and Parkinson’s disease with and without dementia.Dement Geriatr Cogn Disord, 2008, 26(3):218-225.
[16] Kantarci K, Avula R, Senjem ML, et al. Dementia with Lewy bodies and Alzheimer disease:neurodegenerative patterns characterized by DTI. Neurology, 2010, 74(22):1814-1821.
[17] Klucken J, McLean PJ, Gomez-Tortosa E, et al. Neuritic alterations and neural system dysfunction in Alzheimer’s disease and dementia with Lewy bodies. Neurochem Res, 2003, 28(11):1683-1691.
[18] Whitwell JL, Weigand SD, Shiung MM, et al. Focal atrophy in dementia with Lewy bodies on MRh a distinct pattern from Alzheimer’s disease. Brain, 2007, 130(Pt3):708-719.
[19] Sanak D, Nosál’ V, Horák D, et al. Impact of diffusion-weighted MRI-measured initial cerebral infarction volume on clinical outcome in acute stroke patients with middle cerebral artery occlusion treated by thrombolysis. Neuroradiology, 2006, 48(9):632-639.
[20] Kantarci K, Petersen RC, Boeve BF, et al. DWI predicts future progression to Alzheiraer disease in amnestic mild cognitive impairment. Neurology, 2005, 64(5):902-904.
[21] Fellgiebel A, Müller MJ, Wille P, et al. Color-coded diffusiontensor-imaging of posterior cingulate fiber tracts in mild cognitive impairment. Neurobiol Aging, 2005, 26(8):1193-1198.
[22] Zhang B, Li M, Sun ZZ, et al. Evaluation of functional MRI markers in mild cognitive impairment. J Clin Neurosci, 2009, 16(5):635-641.
[23] Mayzel-Oreg O, Assaf Y, Gigi A, et al. High b-value diffusion imaging of dementia:application to vascular dementia and alzheimer disease. J Neurol Sci, 2007, 257(1-2):105-113.
[24] Zhang Y, Schuff N, Du AT, et al. White matter damage in frontotemporal dementia and Alzheimer’s disease measured by diffusion MRI. Brain, 2009, 132(P19):2579-2592.
[25] Matsuo K, Mizuno T, Yamada K, et al. Cerebral white matter damage in frontotemporal dementia assessed by diffusion tensor tractography. Neuroradiology, 2008, 50(7):605-611.
[26] Kantarci K, Reynolds G, Petersen RC, et al. Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease:comparison of 1.5 and 3 T. AJNR Am J Neuroradiol, 2005, 24(5):843-849.
[27] Norfray JF, Provenzale JM. Alzheimer’s disease:neuropathologie findings and recent advances in imaging. AJR Am J Roentgenol, 2004, 182(1):3-13.
[28] Kantarci K, Smith GE, Ivnik RJ, et al.1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer’s disease. J Int Neuropsychol Soe, 2002, 8(7):934-942.
[29] Coulthard E, Firbank M, English P, et al. Proton magnetic resonance spectroscopy in frontotemporal dementia. J Neurol, 2006, 253(7):861-868.
[30] Ernst T, Chang L, Melchor R, et al. Frontotemporal dementia and early Alzheimer disease:differentiation with frontal lobe H-I MR spectroscopy. Radiology, 1997, 203(3):829-836.
[31] Kantarci K, Petersen RC, Boeve BF, et ah 1H MR spectroscopy in common dementias. Neurology, 2004, 63(8):1393-1398.
[32] Liu GR, Gao PY, Lin Y, et al. Brain magnetic resonance elastography on healthy volunteers:a safety study. Acta Radiol, 2009, 50(4):423-429.

相似文献/References:

[1]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
　Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[2]段小艺,李淼,王黎,等.阿尔茨海默病PET正电子药物应用与研究进展[J].国际放射医学核医学杂志,2014,38(5):318.[doi:10.3760/cma.j.issn.1673-4114.2014.05.010]
　Duan Xiao-yi,Li Miao,Wang Li,et al.Application and research progress of PET positron tracers associated with Alzheimer disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):318.[doi:10.3760/cma.j.issn.1673-4114.2014.05.010]
[3]王新艳,管一晖.阿尔茨海默病的影像学诊断进展[J].国际放射医学核医学杂志,2013,37(1):52.[doi:10.3760/cma.j.issn.1673-4114.2013.01.014]
　WANG Xin-yan,GUAN Yi-hui.The advancement in Alzheimer disease of imaging diagnosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):52.[doi:10.3760/cma.j.issn.1673-4114.2013.01.014]
[4]孔艳艳,管一晖,吴平.PET分子探针在阿尔茨海默病早期诊断中的研究进展[J].国际放射医学核医学杂志,2012,36(5):257.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.001]
　KONG Yan-yan,GUAN Yi-hui,WU Ping.Novel PET molecular probes for early diagnosis of Alzheimer’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):257.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.001]
[5]王颖,蔡莉,李彦生,等.11C-PIB PET在不同时期阿尔茨海默病中的研究进展[J].国际放射医学核医学杂志,2013,37(6):378.[doi:10.3760/cma.j.issn.1673-4114.2013.06.013]
　WANG Ying,CAI Li,LI Yan-sheng,et al.Application of 11C-PIB PET in different period of the Alzheimer disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(5):378.[doi:10.3760/cma.j.issn.1673-4114.2013.06.013]
[6]陈贵兵,吴华,彭添兴.正电子显像剂11C-匹兹堡化合物B的化学合成及其临床应用[J].国际放射医学核医学杂志,2008,32(3):158.
　CHEN Gui-bing,WU Hua,PENG Tian-xing.Chemical synthesis and clinical application of a new positron imaging agent 11C-Pittsburgh compound-B[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(5):158.
[7]袁瑛,顾兆祥.放射性核素显像在轻度认知功能障碍中的应用价值[J].国际放射医学核医学杂志,2008,32(4):209.
　YUAN Ying,GU Zhao-xiang.Applications of radionuclide imaging in mild cognitive impairment[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(5):209.
[8]郭喆,张锦明.阿尔茨海默病的放射性分子显像探针研究进展[J].国际放射医学核医学杂志,2006,30(4):199.
　GUO Zhe,ZHANG Jin-ming.Study on radioactive labeling of molecular probes for Alzheimer’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):199.
[9]蔡汉成,尹端沚,张岚,等.早期诊断阿尔茨海默病的PET分子探针[J].国际放射医学核医学杂志,2006,30(4):202.
　CAI Han-cheng,YIN Duan-zhi,ZHANG Lan,et al.PET molecular probes for early detection of Alzheimer’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):202.
[10]李祖贵.轻度认知障碍的功能性神经影像学研究进展[J].国际放射医学核医学杂志,2006,30(2):76.
　LI Zu-gui.The progress of functional neuroimaging in the study of mild cognitive impairment[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):76.

备注/Memo

备注/Memo:
收稿日期:2010-03-25。
基金项目:江苏省卫生厅科研项目(H200740);南京大学博士生自然科学类科研创新计划(CX09B_015Z);南京市卫生局重点项目(ZKX10006)
通讯作者:徐运,E-mail:jumpingzh@yahoo.com.cn
更新日期/Last Update: 1900-01-01